Bayer's ErSO therapy for metastatic breast cancer has not yet entered clinical trials

CompilationTom Lee

Previously, it was reported that ErSO, a small molecule drug from Bayer, has a 95% to 100% success rate for the treatment of cancer cells in animals

This therapy ErSO is a new drug developed by researchers at the University of Illinois in the United States.

In September 2020, Bayer signed an agreement to purchase the development license for the drug for US$370 million and cooperated with Arizona-based Systems Oncology to develop the drug

However, according to the latest reports, since the partnership between the two companies is no longer effective, the two companies' cooperation project on the tumor therapy has also reached a deadlock

Metastatic estrogen receptor-positive breast cancer is the most common type of breast cancer, and there is currently no cure.

ErSO Activism manager Danny Goss expressed his disappointment.

At the same time, Professor Shapiro and his team said they will continue to study ErSO therapy

Reference source:

1.

2.